Advanced Research in Tumor Suppressor
A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Molecular and Translational Medicine".
Deadline for manuscript submissions: closed (30 June 2022) | Viewed by 3204
Special Issue Editor
Special Issue Information
Dear Colleagues,
Chemotherapy is a cytotoxicity reagent that targets DNA or microtubules commonly present in cells. Thus, it has an effect on anticancer activity but also causes side effects such as damage to normal cells. With the identification of the molecular biological character of cancer, targeted therapy that works for specific cancer cells has been developed and received increasing attention. From a molecular and cellular change level, this can minimize side effects because it selectively attacks cancer cells without damaging normal cells. Targeted therapy drugs have been developed that target molecules commonly present in cancer cells, and many studies have reported fewer and less frequent side effects using targeted therapy than current therapy. Moreover, when used in combination with current chemotherapy, the survival rate has been found to be increased. Those studies are particularly encouraging; nevertheless, although targeted therapy has potent effects, there are still several issues that must be resolved. Thus, the mechanism of resistance and increase in drug sensitivity must be identified by studying the target to repress cancer.
Prof. Dr. Dong-Hoon Jin
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- novel target
- biomarker
- target therapy
- small molecule drug
